Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2841-2860 of 3,900 trials

Chronic Spontaneous Urticaria and Hidradenitis Suppurativa: INF904 Study

We are evaluating the safety of an oral medication called INF904 for people with moderate to severe chronic spontaneous urticaria or hidradenitis suppurativa. This study will help us understand how the medication works in the body.

Chronic Spontaneous UrticariaHidradenitis Suppurativa≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Doxapram for Preterm Newborns

We are studying whether doxapram can safely reduce the risk of death and serious developmental problems in preterm newborns compared to a placebo. This research aims to improve outcomes for these vulnerable infants.

Apnea of PrematurityConfirmation phase (III)Standard MedicinesNeurologyPediatrics

Medulloblastoma Treatment: MEMMAT Trial

We are studying a combination of anti-cancer drugs for children with recurrent brain tumors. The goal is to see if this treatment improves response rates and overall survival.

Rare CNS Tumors≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Kidney Disease: VX-147 Study for APOL1 Variants

We are testing the safety and effectiveness of VX-147 in adults and children with APOL1-mediated proteinuric kidney disease. The study aims to see if this treatment can improve kidney function and reduce related health risks.

APOL1-mediated Proteinuric Kidney Disease>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNephrology

Carotid Artery Disease: [18F]AlF-NOTA-octreotide PET/MRI Study

We are exploring a new imaging method to better understand carotid artery disease in patients who have had a recent stroke or TIA. This study aims to see if it can help identify those at risk for future strokes.

Carotid Artery Atherosclerosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Polypoidal Choroidal Vasculopathy: Faricimab Injections

We are studying the effects of faricimab injections on vision improvement in Caucasian patients with polypoidal choroidal vasculopathy. The trial will also assess the treatment's safety and durability.

Polypoidal Choroidal Vasculopathy>2 yearsMonitoring phase (IV)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOphthalmology

Chronic Lymphocytic Leukemia: APG-2575 Study

We are studying a new medication, APG-2575, for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial will evaluate its safety and effectiveness alone and with other treatments.

Chronic Lymphocytic Leukemia (CLL)1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Heart Failure: Sacubitril/Valsartan Treatment

We are studying whether the medication Sacubitril/Valsartan can improve heart function in patients with transthyretin cardiac amyloidosis and heart failure. This trial will help us understand its effects on heart pumping ability.

Transthyretin Cardiac Amyloidosis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Imaging α-Synuclein in the Brain: [18F]ACI-15916

We are testing a new imaging agent to see if it can help identify α-synuclein deposits in the brains of patients suspected of having related conditions. Healthy volunteers are also included to compare results.

Parkinson's DiseaseDementia with Lewy BodiesMultiple System AtrophySafety phase (I)Neurology

Actinic Keratosis: Keramod Gel vs. Aldara Cream

We are studying whether Keramod Gel works better than Aldara Cream for treating actinic keratosis in adults. The trial will also assess safety and how well patients tolerate each treatment.

Actinic Keratosis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesDermatology

Metastatic Tumors: Atezolizumab with SABR

We are studying the effects of a new combination treatment of atezolizumab and radiotherapy for patients with metastatic tumors. This trial aims to see if this approach can help improve survival rates and understand its safety.

Metastatic Tumors3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Colorectal Cancer: Temozolomide and Irinotecan Treatment

We are studying a combination of temozolomide and irinotecan for patients with specific colorectal cancer characteristics after standard chemotherapy. The goal is to see if this treatment helps eliminate remaining cancer cells and improves survival.

Stage II/III Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Chronic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with chronic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Chronic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology

BRCA-related Metastatic Breast Cancer: Pembrolizumab and Carboplatin Study

We are testing a combination of Pembrolizumab and Carboplatin for patients with BRCA-related metastatic breast cancer. The goal is to see if this treatment improves response rates and safety compared to existing options.

Stage IV Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Cancers: AD-O51.4 Safety Study

We are evaluating the safety of a new investigational drug called AD-O51.4 for patients with advanced malignancies. This study aims to understand how well the drug is tolerated in this patient group.

Solid Tumor1-2 yearsSafety phase (I)Oncology

Lung Cancer Treatment: Adagrasib with Pembrolizumab

We are studying whether adding Adagrasib to standard chemotherapy and Pembrolizumab helps patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The trial will also evaluate safety and quality of life.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncology

Ghrelin for Acute Ischemic Stroke Treatment

We are studying whether ghrelin can improve recovery in patients with acute ischemic stroke treated with endovascular thrombectomy. The trial will also assess its effects on overall health and safety over several days.

Ischemic Stroke1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNeurology

Plaque Psoriasis: JNJ-77242113 Study

We are assessing a new treatment for moderate to severe plaque psoriasis to see if it works better than a placebo and an existing medication. This study aims to understand its effectiveness and safety.

Plaque Psoriasis>2 yearsConfirmation phase (III)Investigational MedicinesDermatology

Heart Failure: Engineered Heart Tissue Treatment

We are studying a new type of heart tissue made from stem cells for patients with severe heart failure. The goal is to see if it is safe and effective in improving heart function and related symptoms.

Acute Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Episodic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with episodic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Episodic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology